13 completed. 13 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 6 | Completed 6 |
Follow Refractory Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-cell Lymphoma trials Research Report on Refractory Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 65 | 2021-08-11 | 2026-03-25 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Copanlisib Hydrochloride, Nivolumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2019-12-13 | 2025-03-03 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells - Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2017-10-10 | 2023-02-16 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202 - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Nebraska | 13 | 2016-10-07 | 2023-10-05 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 138 | 2014-03-13 | 2022-02-04 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
| Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant Laboratory Biomarker Analysis, Ruxolitinib Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | University of Nebraska | 71 | 2011-08-12 | 2023-10-05 |
Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Lymphoma, T-Cell (1) · Multiple Myeloma (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoma, B-Cell (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Lymphoma (12) · Neoplasms (12) · Lymphoma, Non-Hodgkin (10) · Hematologic Diseases (4) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2)
Lenalidomide (3) · Nivolumab (3) · Rituximab (3) · Carmustine (2) · Cytarabine (2) · Etoposide (2) · Melphalan (2) · ibrutinib (2) · CT-P10 (1) · Cyclophosphamide (1) · Disulfides (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hematopoietic Stem Cell Transplantation (1) · Immunoglobulin G (1)
BeiGene (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · University of Nebraska (2) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Pharmacyclics LLC. (1) · University of Washington (1)
United States (11) · China (2) · Belgium (1) · Germany (1) · United Kingdom (1)
David Bond, MD (1) · Erel Joffe (1) · Jordan Gauthier (1) · Julie M Vose, MD, MBA (1) · Jutta K. Neuenburg, MD, PhD (1) · Kami Maddocks, MD (1) · Matthew A Lunning, DO (1) · Nabila N Bennani (1) · Paolo Strati (1) · Rahul Banerjee, MD (1) · Yago L Nieto (1)
PMID 27111235, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33942298, PMID 34515338, PMID 34666344, PMID 36618900, PMID 37774014, PMID 39333103, PMID 41595202, PMID 42389828
P30CA036727 (2), P50CA107399 (1), R01CA136551 (1), UM1CA186686 (1), UM1CA186691 (1), UM1CA186709 (1)